申请人:Amberg Wilhelm
公开号:US08686002B2
公开(公告)日:2014-04-01
The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
本发明涉及一般式(I)的化合物,对应的对映异构体、顺反异构体和/或互变异构体形式以及其药学上可接受的盐和前药。本发明还涉及将所述化合物用作5-HT5受体的结合伙伴,用于治疗受5-HT5受体活性调节的疾病,特别是用于治疗神经退行性和神经精神障碍以及其迹象、症状和功能障碍。